Glucose intolerance in familial combined hyperlipidaemia

European Journal of Clinical Investigation

Volumn 28, Issue 1, 1998, Pages 24-32

  Vakkilainen, J ^a   Porkka, K V K ^a   Nuotio, I ^b   Pajukanta, P ^c   Suurinkeroinen, L ^a   Ylitalo, K ^a   Viikari, J S A ^b   Ehnholm, C ^c   Taskinen, M R ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Familial combined hyperlipidaemia; Impaired glucose tolerance; Insulin resistance obesity; Oral glucose tolerance test

Indexed keywords

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; DIABETES MELLITUS; FEMALE; FINLAND; GLUCOSE INTOLERANCE; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PEDIGREE; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; INSULIN RESISTANCE; MALE; MIDDLE AGED; PREVALENCE;

EID: 0031905418     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.00243.x     Document Type: Article

References (41)

1. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. Journal of Clinical Investigation, 1973; 52: 1544-1568.
2. Rose HG, Kranz P, Weinstock M, Juliano J, Haft JI. Inheritance of combined hyperlipoproteinemia: evidence for a new lipoprotein phenotype. American Journal of Medicine, 1973; 54: 148-160.
3. Nikkilä EA, Aro A. Family study of serum lipids and lipoproteins in coronary heart disease. Lancet, 1973; 1: 954-958.
4. Genest JJ, Martin-Munley SS, McNamara JR et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation, 1992; 85: 2025-2033.
5. Venkatesan S, Cullen P, Pacy P, Halliday D, Scott J. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arteriosclerosis and Thrombosis, 1993; 13: 1110-1118.
6. Castro Cabezas M, de Bruin TW, Jansen H, Kock LA, Kortlandt W, Erkelens DW. Impaired chylomicron remnant clearance in familial combined hyperlipidemia. Arteriosclerosis and Thrombosis, 1993; 13: 804-814.
7. Hokanson JE, Austin MA, Zambon A, Brunzell JD. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arteriosclerosis and Thrombosis, 1993; 13: 427-434.
8. Hokanson JE, Krauss RM, Albers JJ, Austin MA, Brunzell JD. LDL physical and chemical properties in familial combined hyperlipidemia. Arteriosclerosis Thrombosis and Vascular Biology, 1995; 15: 452-459.
9. Reynisdottir S, Eriksson M, Angelin B, Arner P. Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia. Journal of Clinical Investigation, 1995; 95: 2161-2169.
10. Sane T, Taskinen M-R. Does familial hypertriglyceridemia predispose to NIDDM? Diabetes Care, 1993; 16: 1494-1501.
11. Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridemia. American Journal of Medicine, 1974; 57: 551-560.
12. Reaven GM, Ida Chen Y-D, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. Journal of Clinical Investigation, 1993; 92: 141-146.
13. Frayn KN. Insulin resistance and lipid metabolism. Current Opinions in Lipidology, 1993; 4: 197-204.
14. Hunt SC, Wu LL, Hopkins PN et al. Apolipoprotein, low density lipoprotein subtraction, and insulin associations with familial combined hyperlipidemia. Study of Utah patients with familial dyslipidemic hypertension. Arteriosclerosis, 1989; 9: 335-344.
15. Castro Cabezas M, de Bruin TW, de Valk HW, Shoulders CC, Jansen H, Willem-Erkelens D. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. Journal of Clinical Investigation, 1993; 92: 160-168.
16. Laakso M. How good a marker is insulin level for insulin resistance? American Journal of Epidemiology, 1993; 137: 959-965.
17. Aitman TJ, Godsland IF, Farren B, Crook D, Wong HJ, Scott J. Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia. Arteriosclerosis Thrombosis and Vascular Biology, 1997; 17: 748-754.
18. Bredie SJH, Cees JJT, Smits P, Stalenhoef AFH. Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their non-affected relatives. Arteriosclerosis Thrombosis and Vascular Biology, 1997; 17: 1465-1471.
19. Koizumi J, Nohara A, Kitatani M et al. Familial combined hyperlipidemia in diabetic patients (abstract). Diabetes, 1996; 45: S137.
20. World Health Organization. Diabetes Mellitus: Report of a WHO Study Group. Technical Report Series 727. Geneva: World Health Organization, 1985.
21. Byrne CD, Wareham NJ, Brown DC et al. Hypertriglyceridaemia in subjects with normal and abnormal glucose tolerance: relative contributions of insulin secretion, insulin resistance and suppression of plasma non-esterified fatty acids. Diabetologia, 1994; 37: 889-896.
22. Phillips DIW, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabetic Med, 1994; 11: 286-292.
23. Gennaro WD, van Norman JD. Quantitation of free, total, and antibody-bound insulin in insulin-treated diabetics. Clinical Chemistry, 1975; 21: 873-879.
24. Miles J, Glasscock R, Aikens J, Gerich J, Raymond M.A microfluorometric method for the determination of free fatty acids in plasma. Journal of Lipid Research, 1983; 24: 96-99.
25. von Röschlau P, Bernt E, Gruber W. Enzymatische Bestimmung des Gesamt-Cholesterins im Serum. Z Klin Chem Klin Biochem, 1974; 12: 403-407.
26. Wahlefeld AW. Triglycerides - Determination after enzymatic hydrolysis. In: Bergmeyer, H.U. ed. Methods of Enzymatic Analysis. New York: Chemie/Academic Press, 1974.
27. Le Floch J-P, Escuyer P, Baudin E, Baudon D, Perlemuter L. Blood glucose under the curve. Methodological aspects. Diabetes Care, 1990; 13: 172-175.
28. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. British Medical Journal, 1990; 300: 230-235.
29. Tuomilehto J, Korhonen HJ, Kartovaara L et al. Prevalence of diabetes mellitus and impaired glucose tolerance in the middle-aged population of three areas in Finland. International Journal of Epidemiology, 1991; 20: 1010-1017.
30. Harris MI, Hadden WC, Knowler WC, Bennert PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US. population aged 20-74 year. Diabetes, 1987; 36: 523-534.
31. Ferrannini E, Vichi S, Beck-Nielsen H et al. Insulin action and age. Diabetes, 1996; 45: 947-953.
32. Kohrt WM, Kirwan JP, Staten MA, Bourey RE, King DS, Holloszy JO. Insulin resistance in aging is related to abdominal obesity. Diabetes, 1993; 42: 273-281.
33. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women. Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes, 1996; 45: 633-638.
34. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. Journal of Clinical Investigation, 1995; 96: 88-98.
35. Reaven GM, Mejean L, Villaume C, Drouin P, Debry G. Plasma glucose and insulin responses to oral glucose in nonobese subjects and patients with endogenous hypertriglyceridemia. Metabolism, 1983; 32: 447-450.
36. Karhapää P, Uusitupa M, Voutilainen E, Laakso M. Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia. Clinical Pharmacology Therapy, 1992; 52: 620-626.
37. Sane T, Knudsen P, Vuorinen-Markkola H, Yki-Järvinen H, Taskinen MR. Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. Metabolism, 1995; 44: 589-596.
38. Sheu WH, Shieh SM, Fuh MM et al. Insulin resistance, glucose intolerance, and hyperinsulinemia. Hypertriglyceridemia vs. hypercholesterolemia. Arteriosclerosis and Thrombosis, 1993; 13: 367-370.
39. Karhapää P, Voutilainen E, Malkki M, Laakso M. Obese men with type IIB hyperlipidemia are insulin resistant. Arteriosclerosis and Thrombosis, 1993; 13: 1469-1475.
40. Karhapää P, Voutilainen E, Kovanen PT, Laakso M. Insulin resistance in familial and nonfamilial hypercholesterolemia. Arteriosclerosis and Thrombosis, 1993; 13: 41-47.
41. Paolisso G, Ferrannini E, Sgambato S, Varricchio M, D'Onofrio F. Hyperinsulinemia in patients with hypercholesterolemia. Journal of Clinical Endocrinology and Metabolism, 1992; 75: 1409-1412.